Literature DB >> 31151934

Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification.

Arieke Suzanna Berendina Kampstra1, Jacqueline Stephanie Dekkers2, Mikhail Volkov2, Annemarie L Dorjée2, Lise Hafkenscheid2, Ayla C Kempers2, Myrthe van Delft2, Theresa Kissel2, Sanne Reijm2, George M C Janssen3, Peter A van Veelen3, Holger Bang4, Tom W J Huizinga2, Leendert A Trouw5, Diane van der Woude2, René E M Toes2.   

Abstract

OBJECTIVES: Autoantibodies against post-translationally modified proteins (anti-modified protein antibodies or AMPAs) are a hallmark of rheumatoid arthritis (RA). A variety of classes of AMPAs against different modifications on proteins, such as citrullination, carbamylation and acetylation, have now been described in RA. At present, there is no conceptual framework explaining the concurrent presence or mutual relationship of different AMPA responses in RA. Here, we aimed to gain understanding of the co-occurrence of AMPA by postulating that the AMPA response shares a common 'background' that can evolve into different classes of AMPAs.
METHODS: Mice were immunised with modified antigens and analysed for AMPA responses. In addition, reactivity of AMPA purified from patients with RA towards differently modified antigens was determined.
RESULTS: Immunisation with carbamylated proteins induced AMPAs recognising carbamylated proteins and also acetylated proteins. Similarly, acetylated proteins generated (autoreactive) AMPAs against other modifications as well. Analysis of anti-citrullinated protein antibodies from patients with RA revealed that these also display reactivity to acetylated and carbamylated antigens. Similarly, anti-carbamylated protein antibodies showed cross-reactivity against all three post-translational modifications.
CONCLUSIONS: Different AMPA responses can emerge from exposure to only a single type of modified protein. These findings indicate that different AMPA responses can originate from a common B-cell response that diversifies into multiple distinct AMPA responses and explain the presence of multiple AMPAs in RA, one of the hallmarks of the disease. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  anti-ccp antibodies; anti-modified protein antibodies; autoantibodies; post-translationally modified proteins; rheumatoid arthritis

Mesh:

Substances:

Year:  2019        PMID: 31151934     DOI: 10.1136/annrheumdis-2018-214950

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

Review 1.  The current status of anti-citrullinated protein antibodies and citrullinated protein-reactive B cells in the pathogenesis of rheumatoid arthritis.

Authors:  Jia He; JiYu Ju; XiaoDong Wang
Journal:  Mol Biol Rep       Date:  2021-12-02       Impact factor: 2.316

2.  The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study.

Authors:  Jagtar S Nijjar; Fraser R Morton; Holger Bang; Christopher D Buckley; Désirée van der Heijde; Ashley Gilmour; Caron Paterson; Iain B McInnes; Duncan Porter; Karim Raza
Journal:  Lancet Rheumatol       Date:  2021-01-27

Review 3.  From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Diane van der Woude; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2022-05-23       Impact factor: 32.286

Review 4.  Redox-Mediated Carbamylation As a Hapten Model Applied to the Origin of Antibodies to Modified Proteins in Rheumatoid Arthritis.

Authors:  Maria Isabel Trejo-Zambrano; Eduardo Gómez-Bañuelos; Felipe Andrade
Journal:  Antioxid Redox Signal       Date:  2021-06-04       Impact factor: 7.468

Review 5.  Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology.

Authors:  Mikhail Volkov; Karin Anna van Schie; Diane van der Woude
Journal:  Immunol Rev       Date:  2019-12-16       Impact factor: 12.988

6.  Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis.

Authors:  Raul Castellanos-Moreira; Sebastian C Rodriguez-Garcia; Sonia Cabrera-Villalba; María José Gomara; Georgina Salvador; Virginia Ruiz-Esquide; Julio Ramirez; Jose Inciarte-Mundo; Rosa Morla; Cristina Garcia-Moreno; Andrea Cuervo; Jose A Gómez-Puerta; Juan D Cañete; Isabel Haro; Raimon Sanmarti
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-10       Impact factor: 5.346

7.  A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis.

Authors:  Caroline Grönwall; Lisa Liljefors; Holger Bang; Aase H Hensvold; Monika Hansson; Linda Mathsson-Alm; Lena Israelsson; Vijay Joshua; Anna Svärd; Ragnhild Stålesen; Philip J Titcombe; Johanna Steen; Luca Piccoli; Natalia Sherina; Cyril Clavel; Elisabet Svenungsson; Iva Gunnarsson; Saedis Saevarsdottir; Alf Kastbom; Guy Serre; Lars Alfredsson; Vivianne Malmström; Johan Rönnelid; Anca I Catrina; Karin Lundberg; Lars Klareskog
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

Review 8.  Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis: Biological Effects and Mechanisms of Immunopathogenesis.

Authors:  Chao-Yi Wu; Huang-Yu Yang; Jenn-Haung Lai
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

Review 9.  [Autoantibodies and the autoreactive immune response : There is more to ACPA than ACPA].

Authors:  H U Scherer
Journal:  Z Rheumatol       Date:  2020-09-24       Impact factor: 1.372

10.  Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases.

Authors:  Jos W G van Rosmalen; Maarten van der Linden; Renato G S Chirivi; Maximilien Euler; Gonny Schmets; Galina Bogatkevich; Konstantinos Kambas; Jonas Hahn; Quinte Braster; Oliver Soehnlein; Markus H Hoffmann; Helmuth H G van Es; Jos M H Raats
Journal:  Cell Mol Immunol       Date:  2020-03-20       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.